Skip to content

Business

Isomorphic Labs raises $5 billion to prepare AI-designed drugs for human trials

Edited and reviewed by AI Ping Editorial Team

3-line summary

  1. Greenoaks and Sequoia co-led the Series C, with additional investment from Alphabet.
  2. The company plans to spend the proceeds on drug design tools and clinical development.
  3. Isomorphic reported preclinical progress and gave no start date for its first human trial.
BeginnerOffice workersBeginners
An empty glass dish beside a dark blue investment folder
AI-generated conceptual image: an investment folder beside an empty glass dish links financing with drug research · AI Ping

Isomorphic Labs said on Nov. 17 that it had raised $5 billion in a Series C round to develop its AI drug design tools and prepare drug candidates for clinical trials. Greenoaks and Sequoia Capital co-led the financing for the Alphabet company. Isomorphic plans to put some of the money into the work needed to move candidates from its own programs and collaborations with drugmakers toward testing in people.

The company reported encouraging preclinical results from its own oncology and immunology programs and from work with partners. Its announcement gave no candidate-level results, identified no drug that would be first into a human study, and set no date for one to begin.

A $5 billion round six months after $2.1 billion

Isomorphic first took outside investment in March 2025, when it raised $600 million in a round led by Thrive Capital. Thrive also led the $2.1 billion Series B, announced on May 12 this year. At the time, Isomorphic said it would use the proceeds to apply its drug design system across more programs and add staff, including people with clinical development experience.

The Series C is about 2.4 times the size of that round. Andreessen Horowitz joined as a new investor alongside the two lead firms. Alphabet put in more money, and Thrive Capital, GV, MGX, CapitalG, Temasek and the UK Sovereign AI Fund returned. Together the three disclosed rounds total $7.7 billion. The Series C announcement gives neither a valuation nor a breakdown by investor.

Three folders in shades of blue arranged in a row
AI-generated conceptual image: three folders represent successive rounds from the first outside investment to Series C · AI Ping

Where the drug programs sit

Demis Hassabis announced Isomorphic in 2021 as a new Alphabet company. Its remit was to carry ideas from DeepMind’s work on predicting protein structures into drug discovery. The two companies released AlphaFold 3 together in May 2024. The model predicts how molecules interact as well as their structures. They made structure prediction available to noncommercial researchers through AlphaFold Server. Isomorphic now works on candidates it owns outright as well as candidates it researches under agreements with pharmaceutical companies.

Eli Lilly and Novartis were among its earliest public partners, signing research deals announced in January 2024. The agreements paired upfront payments of $45 million from Lilly and $37.5 million from Novartis with payments tied to future milestones. In February 2025, Novartis agreed to add up to three research programs on the same financial terms. A collaboration with Johnson & Johnson, announced this January, puts Isomorphic in charge of computational predictions and design, with Johnson & Johnson responsible for experiments and further development.

Isomorphic had already begun assembling a clinical development team. It created a US base in Cambridge, Massachusetts, in June 2025 and named Ben Wolf its chief medical officer. The company said then that he would build a biomedical team at the site and work with colleagues in London and Lausanne. Wolf had previously led clinical trials at Relay Therapeutics. Its latest financing statement says it will expand the infrastructure that helps advance candidates from research into clinical development.

What a first human study would establish

The US Food and Drug Administration describes clinical research as testing in people. Early studies primarily examine safety and dosage, with later studies gathering more evidence about how well a treatment works and what side effects it causes. Sponsors submit an investigational new drug application before beginning clinical research in the United States. The funding announcement gives no recruitment timetable or location for a trial.

A green notebook, an empty glass vial and an undated desk calendar
AI-generated conceptual image: a vial and undated calendar depict clinical preparations with no published trial date · AI Ping

Isomorphic did not break out how much of the Series C it would spend on clinical development or give a timetable for that spending. The release did not specify a country for its first human trial or give a date for a filing with that country’s regulator.

Sources